Phase I trial of emavusertib (CA-4948) in combination with cisplatin, gemcitabine, and durvalumab in patients with untreated advanced or metastatic biliary tract cancer. (ESMO 2026) - Jul 17, 2026 - Abstract #537eTiP; No abstract available
Clinical • Combination therapy • Metastases • P1 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor
|
|
Olivia Aranha; Gregory Fox; Vivian Ortiz; Melissa Meredith; Amberly Brown; Nicholas Waldron; Hailey Sappington; Jingxia Liu; Kian-huat Lim
|